Chief Medical Officer Provides Overview of Preclinical Data Recently Presented at the 2023 American Association of Cancer Research (AACR) annual meeting
Presentations to Highlight Company’s Gene Therapies for Cancer and Diabetes
Provides Preclinical Validation of the ONCOPREX® Nanoparticle Delivery System with a Second Tumor Suppressor Gene
Pre-clinical study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosis in vitro, and suppresses tumor growth in vivo
Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options
Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies
Company to Showcase its Innovate Gene Therapy Programs in Oncology and Diabetes
The gross proceeds from the offering are expected to be approximately $4 million, before deducting placement agent fees and other estimated offering expenses.
Results show statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance compared to baseline
Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Type 1 or Type 2 Diabetes
Designed and Secured by Barsec